Kovitz Investment Group Partners LLC Sells 5,425 Shares of Humana Inc. $HUM

Key Points

• Kovitz Investment Group Partners LLC has reduced its holdings in Humana Inc. by 69.2%, selling 5,425 shares during the first quarter, leaving them with 2,420 shares valued at approximately $640,000.
• Several large investors, including Vanguard Group Inc. and Pzena Investment Management LLC, have increased their positions in Humana, indicating strong institutional interest with 92.38% of the stock currently owned by institutional investors.
• Humana recently missed earnings estimates with an EPS of $6.27, slightly below the consensus forecast of $6.32, though its quarterly revenue rose by 9.6% year-over-year to $32.39 billion.

Kovitz Investment Group Partners LLC reduced its holdings in Humana Inc. (NYSE:HUM - Free Report) by 69.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,420 shares of the insurance provider's stock after selling 5,425 shares during the quarter. Kovitz Investment Group Partners LLC's holdings in Humana were worth $640,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Vanguard Group Inc. grew its position in shares of Humana by 8.9% in the 1st quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider's stock worth $3,697,222,000 after buying an additional 1,143,662 shares during the last quarter. Pzena Investment Management LLC grew its position in shares of Humana by 6.1% in the 1st quarter. Pzena Investment Management LLC now owns 3,828,923 shares of the insurance provider's stock worth $1,013,133,000 after buying an additional 219,541 shares during the last quarter. Davis Selected Advisers grew its position in shares of Humana by 3.3% in the 1st quarter. Davis Selected Advisers now owns 2,331,343 shares of the insurance provider's stock worth $616,873,000 after buying an additional 74,434 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its position in shares of Humana by 11.1% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,605,771 shares of the insurance provider's stock worth $407,401,000 after buying an additional 160,952 shares during the last quarter. Finally, Northern Trust Corp grew its position in shares of Humana by 14.5% in the 4th quarter. Northern Trust Corp now owns 1,216,195 shares of the insurance provider's stock worth $308,561,000 after buying an additional 153,739 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on HUM. Raymond James Financial upgraded Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price objective on the stock in a research report on Thursday, May 1st. Oppenheimer raised their target price on Humana from $300.00 to $310.00 and gave the company an "outperform" rating in a research note on Thursday, May 1st. Bank of America lowered their target price on Humana from $320.00 to $260.00 and set a "neutral" rating for the company in a research note on Tuesday, June 17th. Piper Sandler lowered their target price on Humana from $288.00 to $272.00 and set a "neutral" rating for the company in a research note on Thursday, July 31st. Finally, Robert W. Baird lowered their target price on Humana from $300.00 to $297.00 and set a "neutral" rating for the company in a research note on Friday, July 25th. Seven research analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $281.43.

Humana Stock Up 0.6%

Shares of NYSE:HUM opened at $290.1040 on Thursday. The stock has a fifty day simple moving average of $246.09 and a two-hundred day simple moving average of $253.69. The stock has a market capitalization of $34.89 billion, a price-to-earnings ratio of 22.26, a PEG ratio of 1.70 and a beta of 0.44. Humana Inc. has a 12-month low of $206.87 and a 12-month high of $382.72. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). The company had revenue of $32.39 billion for the quarter, compared to analysts' expectations of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The firm's quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $6.96 EPS. Humana has set its FY 2025 guidance at 17.000- EPS. On average, research analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.